US 2011/0217258 A1Published application

Combined Use of Bendamustine, Doxorubicin and Bortezomib for the Treatment of Multiple Myeloma

AssigneeIndiana University Research and Technology Corporation

InventorSherif S. Farag

Life of this patent

Estimating the term…

Abstract

Methods for treating multiple myeloma by administering a combination of a proteasome inhibitor, bendamustine and doxorubicin are described.

Claims30

Dependent claims

A method for treating multiple myeloma in a subject comprising administering to the subject an effective amount of a combination comprising a proteasome inhibitor, bendamustine and doxorubicin.

Dependencies are inferred from the claim text.

Facts

Application: 13/096,300Filed 28 Apr 2011
Priority: 13 Nov 2008
Published: 8 Sep 2011
Term ends: Not estimatedThe source records don’t support an estimate.

Classification6 codes

A61K 31/4184
1,3-Diazoles: condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/44
Having six-membered rings with one nitrogen as the only ring hetero atom: non condensed pyridines; Hydrogenated derivatives thereof
A61K 31/704
Attached to a carbocyclic compound, e.g. phloridzin: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin,…
A61P 35/00
Antineoplastic agents

Family

Application61/114,284Us provisional application · filed 13 Nov 2008
Application13/096,300Continuation
US 2011/0217258 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results